Labels

Tuesday, December 16, 2008

Evaluation of the ventricular assist device progra...[Health Technol Assess. 2006] - PubMed Result

Evaluation of the ventricular assist device progra...[Health Technol Assess. 2006] - PubMed Result

CONCLUSIONS: There are insufficient data from either published studies or the current study to construct a fair comparison group for VADs. Overall survival of 52% at one year is an excellent clinical achievement for those young patients with rapidly failing hearts. However, if the worst case scenario were plausible, and one could reliably extrapolate results to the lifetime of the patients, VADs would not be cost-effective at traditional thresholds. Further randomised controlled trials are required, using current second generation devices or subsequent devices and conducted in the UK.